重大公告
Announcements
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study
1. Date of occurrence of the event: May 6, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …
Announcements
OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned
1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …
Announcements
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company’s Board of Directors resolved to convene the 2021 Annual General Shareholders’ Meeting
1. Date of the board of directors’ resolution: April 29, 2021 2. General shareholders’ meeting date: June 15, 2021 3. General shareholders’ meeting location: 5th …
Announcements
Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.
1. Date of the board of directors’ resolution: April 29, 2021 2. Type and monetary amount of dividend distribution: N/A 3. Any other matters that …
Announcements
OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned
1. Date of occurrence of the event: April 21, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …